-
A ranar 17 ga Yuli, Cibiyar Kimanta Magunguna (CDE) ta Hukumar Kula da Kayayyakin Lafiya ta Kasa (NMPA) ta sanar da cewa NMPA ta amince da aikace-aikacen tallatawa na Trastuzumab Deruxtecan (Enhertu®) don maganin ciwon daji na biyu a hukumance. Wannan aikace-aikacen yana da alaƙa da...Kara karantawa»
-
Kwanan nan, Ascentage Pharma ta sanar da cewa Hukumar Kayayyakin Lafiya ta Kasa (NMPA) ta amince da sabon maganin Bcl-2 selective inhibitor lisaftoclax (APG-2575) na musamman don magance manyan marasa lafiya da ke fama da cutar sankarar jini ta lymphocytic leukemia/ƙananan lymphocytic lymphoma (CLL/SLL)...Kara karantawa»
-
Kwanan nan, GenFleet Therapeutics ta sanar da cewa Ofishin Gudanar da Magunguna (ISAF) na Yankin Gudanarwa na Musamman na Macau na China ya amince da Dupert® (fulzerasib, GFH925/IBI351) don maganin marasa lafiya da ke fama da cutar kansar huhu ta ƙwayoyin halitta (NSCLC) wacce ke ɗauke da ƙwayar cutar KRAS G12C...Kara karantawa»
-
A ranar 30 ga watan Yuni, kamfanin Avistone mai hana MET Vebreltinib wanda aka samar da kansa ya sami amincewar sharaɗi daga Hukumar Kayayyakin Lafiya ta Ƙasa (NMPA) ta ƙasar Sin don kula da marasa lafiya da ke fama da cutar kansar huhu ta NSCLC da ta bulla a yankinsu ko kuma ta yaɗuwa a cikin ƙwayoyin cuta (MET amplifi)...Kara karantawa»
-
A ranar 30 ga Yuni, 2025, HUTCHMED ta sanar da cewa Hukumar Kayayyakin Lafiya ta Kasa ta China (NMPA) ta amince da amfani da Sabbin Magunguna (NDA) don haɗa ORPATHYS (savolitinib) da TAGRISSO (osimertinib) don maganin marasa lafiya da suka kamu da cutar a gida ko kuma suka kamu da cutar...Kara karantawa»
-
A ranar 30 ga Yuni, shafin yanar gizo na Hukumar Kayayyakin Lafiya ta Kasa (NMPA) ya sanar da cewa Anlotinib, sabon magani na Aji 1 da Chia Tai Tianqing ta samar, ya sami amincewar wani sabon alama a China: maganin hadewa da maganin chemotherapy don maganin marasa lafiya na farko ...Kara karantawa»
-
A ranar 26 ga Yuni, 2025, CARsgen ta sanar da cewa Hukumar Kayayyakin Lafiya ta Kasa (NMPA) ta kasar Sin ta amince da Amfani da Sabbin Magunguna (NDA) don satriccabtagene autoleucel ("satri-cel", CT041) (wani samfurin CAR T-cell mai cin gashin kansa wanda ke adawa da furotin Claudin18.2) don maganin Claudi...Kara karantawa»
-
A ranar 19 ga Yuni, Cibiyar Kimanta Magunguna (CDE) ta Hukumar Kayayyakin Lafiya ta Kasa (NMPA) ta sanar da cewa an gabatar da allurar LM-108 ta Livzon Pharmaceutical don haɗawa a cikin tsarin maganin gaggawa. Haɗin allurar rigakafin ƙwayoyin cuta ta Kefeqibai monoclonal (LM-1...Kara karantawa»
-
A ranar 19 ga Yuni, Cibiyar Kimanta Magunguna (CDE) ta Hukumar Kayayyakin Lafiya ta Kasa (NMPA) ta sanar da cewa an gabatar da shawarar IBI343 ta Innovent Biologics don shiga cikin shirin tantance maganin ci gaba, wanda aka yi niyya don maganin ci gaba a cikin gida ko kuma ciwon daji...Kara karantawa»
-
A ranar 6 ga Yuni, mujallar likitanci ta duniya Journal of Hematology & Oncology ta buga sakamakon binciken mataki na I/II (KL264-01/MK-2870-001) na sabuwar TROP2 ADC sacituzumab tirumotecan (sac-TMT) a matsayin maganin ciwon daji da ba a iya cirewa ba a cikin gida ko kuma wanda ya yi kama da wanda ya yi kama da wanda ba a iya cirewa ba wanda ya...Kara karantawa»
-
A ranar 10 ga Yuni, Cibiyar Kimanta Magunguna (CDE) ta Hukumar Kula da Kayayyakin Lafiya ta Kasa (NMPA) ta sanar da cewa an gabatar da shawarar a ba Trastuzumab Deruxtecan (T-DXd, DS-8201a) fifiko don kula da marasa lafiya manya da ke fama da cutar HER2-positive a gida ko kuma waɗanda suka kamu da cutar...Kara karantawa»
-
Kwanan nan, Merck & Co., Inc. (Merck) ta sanar da cewa Hukumar Kula da Kayayyakin Lafiya ta Kasa (NMPA) ta kasar Sin ta amince da maganin hana PD-1, pembrolizumab, don amfani da shi tare da lenvatinib da kuma transarterial chemoembolization (TACE) don maganin marasa lafiya da ba su da wata illa...Kara karantawa»
Cibiyar likitanci ta haɗin gwiwa ta Asibitin Ciwon Daji na Beijing